Abstract
Originally identified from a T-lymphoblastoid cell line (HUT 102) of a patient diagnosed with a cutaneous T-cell lymphoma, the human T-lymphotropic virus type I (HTLV-I) was the first described human retrovirus (1). In 1981, HTLV-I was established as the etiologic agent for adult T-cell leukemia (ATL) (2), a hematological malignancy first characterized in Japan (3). Since the initial description of ATL and the discovery of HTLV-I, the virus has been associated with an inflammatory, chronic, progressive neurologic disease known as HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP) in addition to several other inflammatory diseases (4–14). Although an increasing number of human diseases have been linked to HTLV-I the vast majority of HTLV-I—infected individuals remain clinically asymptomatic.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.